CORE--AUTOMATED CYTOMETRY & CELL SORTER LABORATORY/CONFOCAL MICROSCOPY

核心——自动化细胞计数

基本信息

  • 批准号:
    6217260
  • 负责人:
  • 金额:
    $ 33.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-07-01 至 2000-06-30
  • 项目状态:
    已结题

项目摘要

The Automated Cytometry and Cell Sorter Laboratory/Confocal Microscopy and Image Analysis Facility provides cellular analysis to investigators with peer-reviewed grants at M.D. Anderson Cancer Center. The facility develops and provides cutting-edge techniques in single-cell analysis. Cell phenotyping, proliferation, and apoptosis assays have been established and modified as needed for multi-parameter analysis. Immunophenotypic analysis was combined with assays of intracellular proteins related to apoptosis (bcl-2, BAG-1, Bcl-Xl, p53, Rb, and fas), proliferation and membrane lipid asymmetry. Quantitation of cellular antigens allow determination of antibody binding capacity per cell. Very rare events and progenitor cell subpopulations have been detected and isolated by three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysis by molecular cytogenetics and other molecular techniques. Acquisition of a high-speed cell sorter and a laser-scanning microscope will provide state-of-the-art isolation and analysis. Laser confocal microscopy has been used extensively, and so the acquisition of a second instrument is necessary. By using a charge coupled-device (CCD)- based image analysis system, a method for image capture in perfect registration was developed and has been used extensively for molecular cytogenetics fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH). FISH has also been combined with the apoptosis assay to detect apoptosis in normal and leukemic cells. The number, phenotype, and proliferation of minimal residual disease cells with abnormalities amenable to FISH analysis can be determined at levels of as few as one malignant cell in 30,000 normal cells. Methods to detect transgene expression in cells have been established using beta- galactosidase (beta-gal), nerve growth factor receptor (NGF-R), and green fluorescent protein. The Facility has served 26 investigators with peer- reviewed grants who used the laser confocal microscope for 1,797 and the FACS facility for 1,970 hours last year, a 33% increase over the last 2 years. The Core has continuously developed new methodology to suit the evolving needs of its users.
自动细胞计数和细胞分选实验室/共聚焦显微镜和 图像分析设备为研究者提供细胞分析, 医学博士的同行评审赠款安德森癌症中心。该设施的发展 并提供单细胞分析的尖端技术。细胞 已经建立了表型、增殖和凋亡测定, 根据多参数分析的需要进行修改。免疫表型分析 结合细胞凋亡相关蛋白的检测 (bcl-2、BAG-1、Bcl-Xl、p53、Rb和fas)、增殖和膜脂质 不对称。细胞抗原的定量允许确定 每个细胞的抗体结合能力。非常罕见的事件和祖细胞 亚群已被检测和分离的三个激光 激发/八参数荧光激活细胞分选(FACS) 随后通过分子细胞遗传学和其他分子生物学方法 技术.获得高速细胞分选仪和激光扫描仪 显微镜将提供最先进的分离和分析。激光 共聚焦显微镜已被广泛使用,因此, 需要第二个工具。通过使用电荷耦合器件(CCD), 的图像分析系统,一种完美的图像捕获方法, 注册已开发并已广泛用于分子 细胞遗传学荧光原位杂交(FISH)和比较 基因组杂交(CGH)。FISH还与 细胞凋亡测定以检测正常和白血病细胞中的细胞凋亡。的 微小残留病细胞的数量、表型和增殖 可通过FISH分析确定的异常水平 3万个正常细胞中只有一个恶性细胞方法来检测 细胞中的转基因表达已经使用β- 半乳糖苷酶(β-gal)、神经生长因子受体(NGF-R)和绿色 荧光蛋白该设施已为26名调查员提供了同行服务, 审查了使用激光共聚焦显微镜的赠款1,797和 去年,FACS设施使用了1,970小时,比过去2年增加了33%。 年核心不断开发新的方法来适应 不断变化的用户需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL ANDREEFF其他文献

MICHAEL ANDREEFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL ANDREEFF', 18)}}的其他基金

Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
  • 批准号:
    10356325
  • 财政年份:
    2022
  • 资助金额:
    $ 33.23万
  • 项目类别:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
  • 批准号:
    10550265
  • 财政年份:
    2022
  • 资助金额:
    $ 33.23万
  • 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
  • 批准号:
    10663157
  • 财政年份:
    2019
  • 资助金额:
    $ 33.23万
  • 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
  • 批准号:
    9806956
  • 财政年份:
    2019
  • 资助金额:
    $ 33.23万
  • 项目类别:
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
P53 激活作为急性髓性白血病的新治疗策略
  • 批准号:
    8499746
  • 财政年份:
    2013
  • 资助金额:
    $ 33.23万
  • 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
  • 批准号:
    7897533
  • 财政年份:
    2010
  • 资助金额:
    $ 33.23万
  • 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
  • 批准号:
    8056055
  • 财政年份:
    2010
  • 资助金额:
    $ 33.23万
  • 项目类别:
Targeting Microenvironment / Leukemia Cell Interactions in CML
CML 中的靶向微环境/白血病细胞相互作用
  • 批准号:
    8000073
  • 财政年份:
    2010
  • 资助金额:
    $ 33.23万
  • 项目类别:
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma
非基因毒性 p53 激活作为淋巴瘤的新治疗概念
  • 批准号:
    7715218
  • 财政年份:
    2009
  • 资助金额:
    $ 33.23万
  • 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
  • 批准号:
    7936811
  • 财政年份:
    2009
  • 资助金额:
    $ 33.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了